Ikena Oncology Inc. (IKNA)
Ikena Oncology Statistics
Share Statistics
Ikena Oncology has 40.26M shares outstanding. The number of shares has increased by -16.58% in one year.
| Shares Outstanding | 40.26M |
| Shares Change (YoY) | -16.58% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 65.71% |
| Shares Floating | 13.81M |
| Failed to Deliver (FTD) Shares | 5.43K |
| FTD / Avg. Volume | 4.74% |
Short Selling Information
The latest short interest is 113.93K, so 0.24% of the outstanding shares have been sold short.
| Short Interest | 113.93K |
| Short % of Shares Out | 0.24% |
| Short % of Float | 0.26% |
| Short Ratio (days to cover) | 1.29 |
Valuation Ratios
The PE ratio is -1.61 and the forward PE ratio is -1.54. Ikena Oncology's PEG ratio is 0.04.
| PE Ratio | -1.61 |
| Forward PE | -1.54 |
| PS Ratio | 0 |
| Forward PS | 2.6 |
| PB Ratio | 0.63 |
| P/FCF Ratio | -1.72 |
| PEG Ratio | 0.04 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Ikena Oncology.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.8, with a Debt / Equity ratio of 0.06.
| Current Ratio | 11.8 |
| Quick Ratio | 11.8 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | -0.13 |
| Debt / FCF | -0.16 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-4.92M |
| Employee Count | 10 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -152K |
| Effective Tax Rate | 0.31% |
Stock Price Statistics
The stock price has increased by -6.2% in the last 52 weeks. The beta is 0.48, so Ikena Oncology's price volatility has been higher than the market average.
| Beta | 0.48 |
| 52-Week Price Change | -6.2% |
| 50-Day Moving Average | 1.3 |
| 200-Day Moving Average | 1.57 |
| Relative Strength Index (RSI) | 50.13 |
| Average Volume (20 Days) | 114.54K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -58.97M |
| Net Income | -49.23M |
| EBITDA | -58.97M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.02 |
Balance Sheet
The company has 39.39M in cash and 7.52M in debt, giving a net cash position of 31.87M.
| Cash & Cash Equivalents | 39.39M |
| Total Debt | 7.52M |
| Net Cash | 31.87M |
| Retained Earnings | -331.62M |
| Total Assets | 141.51M |
| Working Capital | 116.39M |
Cash Flow
In the last 12 months, operating cash flow was -46M and capital expenditures 0, giving a free cash flow of -46M.
| Operating Cash Flow | -46M |
| Capital Expenditures | 0 |
| Free Cash Flow | -46M |
| FCF Per Share | -0.95 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IKNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for IKNA is $3, which is 147.9% higher than the current price. The consensus rating is "Hold".
| Price Target | $3 |
| Price Target Difference | 147.9% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -1.72 |
| Piotroski F-Score | 1 |